Sales of biolitec AG Increase to More Than Euro 39 Million - Aesthetic
Therapies and Ambulant Urology Laser are Growth Drivers - 0.56 Euro
Earnings per Share at June 30, 2007
JENA, Germany, September 28 /PRNewswire-FirstCall/ -- http://www.biolitec.com - biolitec AG, Jena listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409) managed to increase the revenues during the fiscal year ending June, 30 2007 by 34 % to Euro 39.04 million (previous year: Euro 29.1 million). The gross profit amounted to Euro 26.5 million (last fiscal year Euro 19.8 million) and the EBIT increased by 191% to Euro 6.7 million (last fiscal year Euro 2.3 million). The operating profit increased by 183 % from Euro 2.4 million to Euro 6.9 million.
Due to the strong sales increase especially with aesthetic treatment methods (ELVeS(TM) etc.) as well as for the BPH treatment and in the disposable business the net income increased to Euro 5.6 million (last fiscal year Euro 2.1 million). Continuous high R&D investments (Euro 5.5 million, 14% of sales) are necessary to ensure the groups long term growth and profitability.
Cash also benefited from the positive results and order situation with an increase to Euro 4.3 million in fiscal year 2006/2007; as the company is nearly free of debt a sound basis for further growth financing is given.
The strongest increase with 78 % respectively 17 % were achieved in our traditional fields' lasers and fibres/probes. The significant contribution of biolitec's turnover once again was achieved in Europe and North America. Due to the strong growth in the USA the North American share of overall sales increased to 48% (last year 41 %).
"biolitec AG expects for the current fiscal year further dynamic growth as well as an improved EBIT. The basis for this accelerated growth lies in the during the expired fiscal year achieved growth of sales of disposables especially from the field of aesthetics as well as the increase of installed equipment base of the ELVeS(TM) and urology lasers. Future growth is also expected to be generated with aesthetics as well as in urology", explains Dr. Wolfgang Neuberger, CEO of biolitec AG. Per June 30, 2007 earnings per share amounts to 0.56 Euro.
The field of urology shows impressively biolitec's innovative power. For the first time, patients suffering from benign prostate hyperplasia can be treated in office with biolitec's urology laser LIFE (Laser Induced Flow Enhancement). For the therapy of prostate enlargement biolitec's BPH treatment method LIFE avoids, in contrast to standard surgery, a stay in hospital for several days. The method guarantees a minimal convalescence and reduces the risks of incontinence and impotence. The laser is the only possibility to treat benign prostate hyperplasia in office without extensive anaesthesia.
First LIFE Laser Centers have already been established in Germany, more of them are going to be established, mostly in metropolitan areas. The therapy has already been used successfully in the USA since the beginning of this year.
biolitec is the only supplier for photodynamic therapy worldwide that offers all relevant core competencies - photosensitizers, lasers and optical fibers. Besides minimal invasive laser treatments and the oncology business biolitec has successfully developed competencies in the field of aesthetics. biolitec is listed in the Prime Standard under ISIN DE0005213409. For more informations: http://www.biolitec.com .
Phone : +49-(0)-69/959083-20
Fax : +49-(0)-69/959083-99
|SOURCE biolitec AG|
Copyright©2007 PR Newswire.
All rights reserved